Compound
One tablet of Rinza Lorcept contains: amylmetacresol - 600 mcg, 2,4-dichlorobenzyl alcohol - 1.2 mg.
Excipients: citric acid monohydrate , anise oil, dextrose, sucrose, mint oil, orange oil, sunset yellow dye, orange oil, azorubine dye, blackcurrant flavor, honey flavor, brilliant blue dye.
One tablet of Rinza Lorcept Anesthetics contains: amylmetacresol - 600 mcg, 2,4-dichlorobenzyl alcohol - 1.2 mg, lidocaine hydrochloride monohydrate - 10 mg.
Lorcept lozenges with orange flavor No. 10x2
Name
Lorcept tablet/dispersible with orange flavor 1.5 mg in container pack No. 10x2
Description
The tablets are round, biconvex, white or white with a yellowish tint, with an orange flavor.
Main active ingredient
cetylpyridinium chloride
Release form
lozenges
Dosage
1.5 mg
Indications for use
Local auxiliary treatment of infectious and inflammatory diseases of the mucous membrane of the oral cavity and pharynx.
Directions for use and doses
Adults and teenagers: Slowly dissolve 1 tablet every 2 hours. The daily dose should not exceed 8 tablets. Children over 6 years of age: slowly dissolve 1 tablet every 4 hours. The daily dose should not exceed 4 tablets. Special categories of patients: Patients with impaired liver function - with caution (see section "Precautions"). Patients with impaired renal function - there is no data on the need for dose adjustment. Elderly patients - there is no data on the need for dose adjustment.
Use during pregnancy and lactation
Due to the lack of sufficient data, use during pregnancy and breastfeeding is not recommended.
The ability to influence the reaction rate when driving a vehicle or working with other mechanisms
Does not affect.
Precautionary measures
If a bacterial infection is suspected, systemic antibiotic therapy should be prescribed. For viral lesions of the oral mucosa, cetylpyridinium monotherapy should be critically reviewed. Cetylpyridinium chloride should not be used when mucous membranes are damaged due to possible problems with wound healing. Patients with contact allergies should not use cetylpyridinium. Patients with rare hereditary problems of fructose intolerance should not take this medicine. Due to the presence of mint oil in the drug, use with caution in patients with inflammatory diseases of the gastrointestinal tract, liver and biliary tract, hiatal hernia. Due to the lack of available information on the use of peppermint oil in pediatrics, the drug is recommended for use in children under medical supervision.
Interaction with other drugs
Quaternary ammonium compounds are inactivated by serum proteins, purulent exudate, as well as phospholipids and other lipid-containing substances. It is not recommended to take lozenges with milk, as their antimicrobial activity may be reduced. The use of anionic surfactants (for example, toothpaste) reduces the effectiveness of cetylpyridinium chloride.
Contraindications
Hypersensitivity to cetylpyridinium, menthol and other auxiliary components of the drug. Hypersensitivity of the respiratory tract, bronchospastic reactions, bronchial asthma. History of seizures (including febrile) in children. Do not use in areas of wounds or damage to the mucous membrane. Children's age up to 6 years.
Compound
Composition of lozenges with orange flavor: active substance: cetylpyridinium chloride 1.5 mg; excipients: sorbitol, menthol, orange flavor additive (maltodextrin, natural rubber, gum arabic (E414), natural orange oil, purified water), calcium stearate, talc.
Overdose
Cases of overdose of cetylpyridinium have not been described. High oral doses of cationic surfactants such as cetylpyridinium chloride may cause nausea, vomiting, convulsions, poor circulation, and coma. In case of overdose, the development of hemolysis cannot be ruled out. Measures should be taken to reduce the absorption of the drug. If necessary, gastric lavage. Symptomatic therapy is prescribed.
Side effect
From the immune system: hypersensitivity reactions. From the gastrointestinal tract: ulceration of the oral mucosa, transient brownish discoloration of the tongue and teeth, burning sensation, nausea, vomiting. The frequency of the above adverse reactions is not known. Possible disruption of wound healing and damage to the mucous membrane. Sensitization to cetylpyridinium may develop.
Storage conditions
Store at a temperature not exceeding 25 °C, protected from moisture and light, out of the reach of children.
Release form
The drug is a lozenge (orange - orange, lemon - yellow, honey-lemon - brown, blackcurrant - purple), biconvex, round, with an uneven surface. Possible uneven coloring, presence of air inclusions and slight uneven edges.
Release options for Rinza Lorcept:
- 4 such tablets in a strip package; 2, 3 or 4 such strip packages in a cardboard box;
- 8 such tablets in a blister; 3 or 2 such blisters in a cardboard pack;
- 8 such tablets in a blister; 3 or 2 such blisters in a multilayer laminated bag, one such bag in a cardboard box.
Release for Rinza Lorsept Anesthetics: 8 such tablets in a blister pack; two such packages in a cardboard box.
Oralsept®
Benzydamine hydrochloride is a non-steroidal anti-inflammatory drug, an indazole derivative, without a carboxyl group.
The absence of a carboxyl group gives the following features: benzydamine is a weak base (whereas most NSAIDs are weak acids), has high lipophilicity, penetrates well into the site of inflammation along the pH gradient (where the pH is lower) and accumulates in therapeutic concentrations.
It has an anti-inflammatory and local analgesic effect, has an antiseptic (against a wide range of microorganisms), as well as an antifungal effect.
The anti-inflammatory effect of the drug is due to a decrease in capillary permeability, stabilization of cell membranes due to inhibition of the synthesis and inactivation of prostaglandins, histamine, bradykinin, cytokines, complement factors and other nonspecific endogenous “damaging” factors. Benzidamine suppresses the production of proinflammatory cytokines, especially tumor necrosis factor-α (TNF-α), and to a lesser extent interleukin-1β (IL-1β). The main feature of benzydamine is that while it is a weak inhibitor of prostaglandin synthesis, it demonstrates potent inhibition of proinflammatory cytokines. For this reason, benzydamine may be classified as a cytokine-suppressing anti-inflammatory drug.
The local anesthetic effect of benzydamine is associated with the structural features of its molecule, similar to local anesthetics. The analgesic effect is due to an indirect decrease in the concentration of biogenic amines, which have algogenic properties, and an increase in the pain sensitivity threshold of the receptor apparatus; benzydamine also blocks the interaction of bradykinin with tissue receptors, restores microcirculation and reduces pain sensitivity at the site of inflammation.
Benzidamine has an antibacterial effect due to rapid penetration through the membranes of microorganisms with subsequent damage to cellular structures, disruption of metabolic processes and cell lysosomes.
Has antifungal effect against 20 strains of Candida albicans
and
non-albicans
strains, causing structural modifications to the fungal cell wall and their metabolic circuits, thus preventing their reproduction.
Pharmacodynamics and pharmacokinetics
Pharmacodynamics
The effectiveness of this drug is ensured by the presence of two antibacterial components - 2,4-dichlorobenzyl alcohol and amylmetacresol . They act on a wide range of gram-positive and gram-negative bacteria ( staphylococci , fusobacteria , pneumococci and especially Pseudomonas aeruginosa, Staphylococcus aureus, Branhamella catarrhalis, Haemophilus influenzae), and also have an antifungal effect. Protects against secondary bacterial infections of the throat due to viral respiratory diseases. The natural medicinal components of the drug soften the inflamed mucous membrane.
2,4-dichlorobenzyl alcohol dehydrates microbial cells.
Amylmetacresol disrupts the protein structure of bacteria, ensuring their death.
Lidocaine has a strong local anesthetic effect.
Pharmacokinetics
There is practically no absorption of the drug components into the systemic circulation.
Instructions for use
Pharmacodynamics
Benzydamine hydrochloride is a non-steroidal anti-inflammatory drug, an indazole derivative, without a carboxyl group. The absence of a carboxyl group gives the following features: Benzidamine is a weak base (whereas most NSAIDs are weak acids), has high lipophilicity, penetrates well into the site of inflammation along the pH gradient (where the pH is lower) and accumulates in therapeutic concentrations.
It has an anti-inflammatory and local analgesic effect, has an antiseptic (against a wide range of microorganisms), as well as an antifungal effect.
The anti-inflammatory effect of the drug is due to a decrease in capillary permeability, stabilization of cell membranes due to inhibition of the synthesis and inactivation of prostaglandins, histamine, bradykinin, cytokines, complement factors and other nonspecific endogenous “damaging” factors.
Benzidamine suppresses the production of proinflammatory cytokines, especially tumor necrosis factor-α (TNF-α), and to a lesser extent interleukin-1β (IL-1β). The main feature of benzydamine is that, being a weak inhibitor of prostaglandin synthesis, it demonstrates powerful inhibition of proinflammatory cytokines. For this reason, benzydamine may be classified as a cytokine-suppressing anti-inflammatory drug.
The local anesthetic effect of benzydamine is associated with the structural features of its molecule, similar to local anesthetics. The analgesic effect is due to an indirect decrease in the concentration of biogenic amines, which have algogenic properties, and an increase in the pain sensitivity threshold of the receptor apparatus; benzydamine also blocks the interaction of bradykinin with tissue receptors, restores microcirculation and reduces pain sensitivity at the site of inflammation.
Benzidamine has an antibacterial effect due to rapid penetration through the membranes of microorganisms with subsequent damage to cellular structures, disruption of metabolic processes and cell lysosomes.
It has an antifungal effect against 20 strains of Candida albicans and non-albicans strains, causing structural modifications of the cell wall of fungi and their metabolic chains, thus preventing their reproduction.
Pharmacokinetics
When applied topically, it is well absorbed through the mucous membranes and quickly penetrates into inflamed tissues; it is found in the blood plasma in quantities insufficient to obtain systemic effects. It is excreted mainly by the kidneys and through the intestines in the form of metabolites or conjugation products.
Analogs
Level 4 ATC code matches: Falimint
Suprima-ENT
Ingalipt-N
Strepsils Plus
Strepsils
Ingalipt
TheraFlu LAR
Hexoral Tabs
Lisak
Efizol
Angilex
Kameton
Anzibel
Agisept
Yox
Lugol's solution with glycerin
Lugol
Laripront
Stopangin 2A
Stopangin
Analogues of the drug are: Neo-Angin , Strepsils Plus , Trisils , Hexoral , Hexoral Lorsept .
